The health agency sets the terms for lifting the pause in the launch of Johnson & Johnson’s COVID-19 vaccine.
The South African health authority has recommended that the government lift the hiatus in the administration of the COVID-19 vaccine from drug company Johnson & Johnson because of certain conditions.
“These conditions include, but are not limited to, increased screening and monitoring of participants who are at high risk for a bleeding disorder,” the South African Health Products Regulatory Authority (SAHPRA) said Saturday.
“In addition, measures are to be taken to ensure the safe management of all participants who develop vaccine-induced thrombosis and thrombocytopenia (VITT),” the statement said.
SAHPRA said Wednesday that it recently reviewed data from Johnson & Johnson’s local research study on the immunization of health care workers and found no significant safety concerns.
South Africa suspended the launch of the J&J vaccine in the “Implementation Study” on Tuesday after US health officials recommended that its use be discontinued because of rare cases of blood clots in six people vaccinated with it, out of approximately seven million people, who did this received the shot in the country.
A U.S. panel will meet again next week to discuss whether to continue the hiatus in vaccine use after a vote on the issue was postponed earlier this week.